The FDA has granted orphan drug status to S-oxprenolol as a treatment for ALS. This designation is a significant step forward in the development of potential therapies for this debilitating disease. S-oxprenolol has shown promise in early studies as a treatment for ALS, and this orphan drug status will help to expedite its development and availability to patients in need. This news brings hope to the ALS community and represents a positive advancement in the fight against this devastating condition.
Subscribe
Login
0 Comments